- Home
- ATNF vs MBRX Comparison
ATNF vs MBRX Comparison
Compare ATNF & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- MBRX
- Stock Information
- Founded
- ATNF 2016
- MBRX 2015
- Country
- ATNF United States
- MBRX United States
- Employees
- ATNF N/A
- MBRX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- MBRX Health Care
- Exchange
- ATNF Nasdaq
- MBRX Nasdaq
- Market Cap
- ATNF 4.1M
- MBRX 4.4M
- IPO Year
- ATNF N/A
- MBRX 2016
- Fundamental
- Price
- ATNF $0.86
- MBRX $0.87
- Analyst Decision
- ATNF
- MBRX Strong Buy
- Analyst Count
- ATNF 0
- MBRX 3
- Target Price
- ATNF N/A
- MBRX $17.33
- AVG Volume (30 Days)
- ATNF 35.6K
- MBRX 667.1K
- Earning Date
- ATNF 05-14-2025
- MBRX 05-09-2025
- Dividend Yield
- ATNF N/A
- MBRX N/A
- EPS Growth
- ATNF N/A
- MBRX N/A
- EPS
- ATNF N/A
- MBRX N/A
- Revenue
- ATNF N/A
- MBRX N/A
- Revenue This Year
- ATNF N/A
- MBRX N/A
- Revenue Next Year
- ATNF N/A
- MBRX N/A
- P/E Ratio
- ATNF N/A
- MBRX N/A
- Revenue Growth
- ATNF N/A
- MBRX N/A
- 52 Week Low
- ATNF $0.90
- MBRX $0.40
- 52 Week High
- ATNF $17.75
- MBRX $5.91
- Technical
- Relative Strength Index (RSI)
- ATNF 36.88
- MBRX 38.28
- Support Level
- ATNF $0.90
- MBRX $0.92
- Resistance Level
- ATNF $1.02
- MBRX $1.04
- Average True Range (ATR)
- ATNF 0.07
- MBRX 0.10
- MACD
- ATNF 0.00
- MBRX -0.01
- Stochastic Oscillator
- ATNF 37.01
- MBRX 3.21
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.